
GEHC Stock Forecast & Price Target
GEHC Analyst Ratings
Bulls say
GE HealthCare Techs is supported by a diversified, recurring-heavy model, with roughly half of revenue recurring through service, pharmaceutical diagnostics, and digital solutions, while its imaging and ultrasound leadership gives it scale across a $90 billion market. Its outlook is strengthened by healthy capital book-to-bill trends, backlog of $23.9 billion as of 2Q26, and management’s ability to convert growth into earnings through cost discipline, tariff mitigation, and a medium-term operating margin target of 17-20%+. The Sofie Biosciences acquisition for $945 million in cash should further enhance the radiopharmaceuticals portfolio, add a phase 3 asset, and be accretive to revenue growth, operating margin, and EPS in the first full year.
Bears say
GE HealthCare Techs is viewed cautiously because its bear case assumes only low-single-digit revenue growth, which would translate into slower earnings growth and reflects sensitivity to a weak macro backdrop. Hospital capital budget pressure could dampen demand for capital equipment and related services, while China remains a key overhang: revenue mix fell from 15% in 2021 to 11% in 2025 and has been a 60 bps to 140 bps growth headwind since 2021 and 2024. Tariffs and inflation have also pressured execution, with $250 million of tariff impact in 2025 and materially higher inflation, raising concern that cost savings may constrain commercial activity, R&D, and the pipeline.
This aggregate rating is based on analysts' research of GE HealthCare Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.
GEHC Analyst Forecast & Price Prediction
Start investing in GEHC
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About GE HealthCare Technologies Inc (GEHC) Forecast
GEHC Analyst Forecast & Price Prediction
Start investing in GEHC
Order type
Buy in
Order amount
Est. shares
0 shares